Recombinant IL-9 antibodies and uses thereof

• US 20050002934A1
• Filed: 04/12/2004
• Published: 01/06/2005
• Est. Priority Date: 04/11/2003
• Status: Active Grant

• Current Assignee: Medimmune LLC (Astrazeneca PLC)
• Original Assignee: Medimmune Incorporated (Astrazeneca PLC)
• Inventors: Reed, Jennifer Lynne
• Granted Patent: US 7,354,584 B2
• Time in Patent Office: Days
• US Class Current: 424/145.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/10 Antimycotics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/244 : Interleukins [IL]
• CPC Class Codes: C07K 2317/24 : containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/76 : Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 : Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 33/6869 : Interleukin

Abstract

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

Claims

1. An IL-9 antibody comprising a variable heavy (VH) domain having an amino acid sequence of the VH domain of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide.

3. The IL-9 antibody of claim 1 further comprising a VL domain having an amino acid sequence of the VL domain of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

85. The IL-9 antibody of claim 1, 2 or 3, wherein the antibody is a human or humanized antibody.

86. The IL-9 antibody of claim 1, 2 or 3, wherein the antibody is conjugated to a detectable substance or a therapeutic agent.

87. A pharmaceutical composition comprising the IL-9 antibody of claim 1, 2 or 3, and a pharmaceutically acceptable carrier.

88. A method for preventing, treating, managing and/or ameliorating a disease or disorder characterized by aberrant expression and/or activity of an IL-9 polypeptide or aberrant expression and/or activity of an IL-9R, said method comprising administering to a subject in need thereof an prophylactically or therapeutically effective amount of the IL-9 antibody of claim 1, 2 or 3.

89. A method for preventing, treating, managing and/or ameliorating an inflammatory disorder, autoimmune disorder, a proliferative disorder or respiratory infection or one or more symptoms thereof, said comprising administering to a subject in need thereof a dosage of a prophylactically or therapeutically effective amount of the IL-9 antibody of claim 1, 2 or 3.

90. The method of claim 89, wherein the respiratory infection is caused by a virus or bacteria.

91. The method of claim 89, wherein the virus is respiratory syncytial virus, parainfluenza virus or human metapneumovirus.

92. The method of claim 89, wherein the inflammatory disorder is asthma, an allergy, arthritis or a disorder characterized by type 2-mediated inflammation.

93. The method of claim 89, wherein the autoimmune disorder is rheumatoid arthritis or multiple sclerosis.

94. The method of claim 89 further comprising a dosage of a prophylactically or therapeutically effective amount of one or more prophylactic or therapeutic agents other than an IL-9 antibody.

95. The method of claim 94, wherein at least one of the prophylactic or therapeutic agents is an anti-angiogenic agent, a TNF-α

antagonist, an immunomodulatory agent, or an anti-inflammatory agent.

96. The method of claim 95, wherein the anti-angiogenic agent is VITAXIN™

.

97. The method of claim 95, wherein the immunomodulatory agent is MEDI-507 or an anti-Epha2 antibody.

98. The method of claim 89, wherein the IL-9 antibody is administered parenterally, intranasally or orally.

99. The method of claim 89, wherein the subject is refractory to conventional therapies for the disease or disorder.

100. A method of diagnosing, prognosing, or monitoring a disorder or disease characterized by aberrant expression and/or activity of an IL-9 polypeptide or aberrant expression and/or activity of an IL-9R comprising:

(a) assaying the level of IL-9 in cells or a tissue sample of a subject using the IL-9 antibody claim of 1, 2 or 3; and

(b) comparing the assayed level of IL-9 with a control level, whereby an increase or decrease in the assayed level of IL-9 compared to the control level of IL-9 is indicative of said disorder or disease.

101. A kit comprising the antibody of claim 1, 2 or 3 and instructions for use, in one or more containers.

102. An article of manufacture comprising a packaging material and a pharmaceutical agent contained within said packaging material, wherein said pharmaceutical agent comprises the IL-9 antibody of claim 1, 2 or 3 and a pharmaceutically acceptable carrier.

2. An IL-9 antibody comprising a variable light (VL) domain having an amino acid sequence of the VL domain of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide.

4. An IL-9 antibody comprising a complementarity determining region (CDR) having an amino acid sequence of a CDR of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4, wherein the said antibody immunospecifically binds to a human IL-9 polypeptide.

5. The IL-9 antibody of claim 4, wherein the antibody comprises a VH CDR having an amino acid sequence of a VH CDR of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

6. The IL-9 antibody of claim 4, wherein the antibody comprises a VL CDR having an amino acid sequence of a VL CDR of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

7. The IL-9 antibody of claim 5 further comprising a VL CDR having the amino acid sequence of a VL CDR of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

8. The IL-9 antibody of claim 5, wherein the antibody comprises a VH CDR1 having an amino acid sequence of a VH CDR1 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

9. The IL-9 antibody of claim 5, wherein the antibody comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

10. The IL-9 antibody of claim 5, wherein the antibody comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

11. The IL-9 antibody of claim 8, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

12. The IL-9 antibody of claim 8, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

13. The IL-9 antibody of claim 9, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

14. The IL-9 antibody of claim 11, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

15. The IL-9 antibody of claim 7, wherein the antibody comprises a VH CDR1 having an amino acid sequence of a VH CDR1 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

16. The IL-9 antibody of claim 7, wherein the antibody comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

17. The IL-9 antibody of claim 7, wherein the antibody comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

18. The IL-9 antibody of claim 15, wherein the antibody further comprises a VH CDR2 having an amino acid sequence of a VH CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

19. The IL-9 antibody of claim 15, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

20. The IL-9 antibody of claim 16, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

21. The IL-9 antibody of claim 18, wherein the antibody further comprises a VH CDR3 having an amino acid sequence of a VH CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

22. The IL-9 antibody of claim 6, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

23. The IL-9 antibody of claim 6, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

24. The IL-9 antibody of claim 6, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

25. The IL-9 antibody of claim 22, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

26. The IL-9 antibody of claim 22, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

27. The IL-9 antibody of claim 23, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

28. The IL-9 antibody of claim 25, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

29. The IL-9 antibody of claim 7, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

30. The IL-9 antibody of claim 7, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

31. The IL-9 antibody of claim 7, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

32. The IL-9 antibody of claim 29, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

33. The IL-9 antibody of claim 29, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

34. The IL-9 antibody of claim 30, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

35. The IL-9 antibody of claim 32, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

36. The IL-9 antibody of claim 15, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

37. The IL-9 antibody of claim 15, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4t)₄com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

38. The IL-9 antibody of claim 15, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

39. The IL-9 antibody of claim 36, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

40. The IL-9 antibody of claim 36, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

41. The IL-9 antibody of claim 37, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

42. The IL-9 antibody of claim 39, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

43. The IL-9 antibody of claim 16, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

44. The IL-9 antibody of claim 16, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

45. The IL-9 antibody of claim 16, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

46. The IL-9 antibody of claim 43, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

47. The IL-9 antibody of claim 43, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

48. The IL-9 antibody of claim 44, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

49. The IL-9 antibody of claim 46, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

50. The IL-9 antibody of claim 17, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

51. The IL-9 antibody of claim 17, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

52. The IL-9 antibody of claim 17, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

53. The IL-9 antibody of claim 50, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

54. The IL-9 antibody of claim 50, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

55. The IL-9 antibody of claim 51, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

56. The IL-9 antibody of claim 53, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

57. The IL-9 antibody of claim 18, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

58. The IL-9 antibody of claim 18, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

59. The IL-9 antibody of claim 18, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

60. The IL-9 antibody of claim 57, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

61. The IL-9 antibody of claim 57, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

62. The IL-9 antibody of claim 58, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

63. The IL-9 antibody of claim 60, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

64. The IL-9 antibody of claim 19, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

65. The IL-9 antibody of claim 19, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

66. The IL-9 antibody of claim 19, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

67. The IL-9 antibody of claim 64, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

68. The IL-9 antibody of claim 64, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

69. The IL-9 antibody of claim 65, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

70. The IL-9 antibody of claim 67, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

71. The IL-9 antibody of claim 20, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

72. The IL-9 antibody of claim 20, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

73. The IL-9 antibody of claim 20, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

74. The IL-9 antibody of claim 71, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

75. The IL-9 antibody of claim 71, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

76. The IL-9 antibody of claim 72, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

77. The IL-9 antibody of claim 74, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

78. The IL-9 antibody of claim 21, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

79. The IL-9 antibody of claim 21, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

80. The IL-9 antibody of claim 21, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

81. The IL-9 antibody of claim 78, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

82. The IL-9 antibody of claim 78, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

83. The IL-9 antibody of claim 79, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

84. The IL-9 antibody of claim 81, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 of 4D4, 4D4H2-1 D11, 4D4com-XF9, 4D4com-2F9, 7F3, 71A10, 22D3, 7F3com-2H2, 7F3com-3H5, or 7F3com-3D4.

103. An IL-9 antibody, wherein said IL-9 antibody has an association rate constant or k_on rate of at least 10⁵ M⁻

1 s<sup>−

1</sup>.

104. The IL-9 antibody of claim 103, wherein said association rate constant or k_on rate is at most 10¹¹ M⁻

1 s<sup>−

1</sup>.

105. An IL-9 antibody, wherein said IL-9 antibody has a dissociation rate constant or k_off rate of less than about 2×

10<sup>−

4</sup> s<sup>−

1</sup>.

106. The IL-9 antibody of claim 105, wherein said dissociation rate constant or k_off is greater than 10⁻

11 s<sup>−

1</sup>.

107. An IL-9 antibody, wherein said IL-9 antibody has an affinity constant (K_a) of at least 10⁷ M⁻

1.

108. The antibody of claim 107, wherein said affinity constant is at most 5×

10¹¹ M<sup>−

3</sup>.

109. An IL-9 antibody, wherein said IL-9 antibody has dissociation constant (K_d) of less than 10⁻

9 M.

110. The antibody of claim 109, wherein said dissociation constant is greater than 6×

10<sup>−

12</sup> M.